Loading
A phase 2 trial of Sacituzumab tirumotecan, KL-A167, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. is a phase 2 interventional study registered as NCT05351788 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 110 participants planned, started 2022-05-20 and due to reach its primary completion in 2026-08. Interventions recorded: SKB264, KL-A167, Carboplatin, Cisplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares KL-A167, Sichuan Kelun-Biotech, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Cisplatin, Carboplatin.
Shares Sichuan Kelun-Biotech, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KL-A167, Sichuan Kelun-Biotech.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/